ImmunoCellular Therapeutics (NASDAQ:IMUC) released its earnings data on Monday. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.06) by $0.02, American Banking News.com reports.
A number of research firms have recently commented on IMUC. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $3.31.
ImmunoCellular Therapeutics (NASDAQ:IMUC) opened at 0.9159 on Monday. ImmunoCellular Therapeutics has a 52-week low of $0.65 and a 52-week high of $4.00. The stock’s 50-day moving average is $1.03 and its 200-day moving average is $1.19. The company’s market cap is $53.1 million.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.